A short update confirms trading for the year will be in line with market expectations, including the recent licensing deal with Organogenesis for the group’s new anti-microbial foam product. We now upgrade our estimates to include this (FY17/18 EPS +8.0%/3.4%), leaving all other estimates unchanged. While we continue to view AMS as a high quality, well managed business, the current valuation remains out of kilter with the organic growth outlook and the lack of synergies between the group’s two m ....
14 Dec 2017
N+1 Singer - Advanced Medical Solutions - In line FY trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Advanced Medical Solutions - In line FY trading update
Advanced Medical Solutions Group plc (AMS:LON) | 183 -1.5 (-0.4%) | Mkt Cap: 397.5m
- Published:
14 Dec 2017 -
Author:
Chris Glasper -
Pages:
3
A short update confirms trading for the year will be in line with market expectations, including the recent licensing deal with Organogenesis for the group’s new anti-microbial foam product. We now upgrade our estimates to include this (FY17/18 EPS +8.0%/3.4%), leaving all other estimates unchanged. While we continue to view AMS as a high quality, well managed business, the current valuation remains out of kilter with the organic growth outlook and the lack of synergies between the group’s two m ....